After 12 months, researchers found that the device was associated with control of AFib in 99% of patients and relief from AFib symptoms in 93.1% of patients.
Could this late-breaking clinical trial from TCT 2023 be a sign of things to come in the years ahead? Samir Kapadia, MD, explored the topic in a new interview.